Additional US$ 4 million received for next development steps of MedinCell’s 6-month active injectable bioresorbable subcutaneous contraceptive
November 30, 2022
November 30, 2022
MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
November 7, 2022
November 7, 2022
MedinCell signs a licence agreement with the Medicines Patent Pool to fight malaria transmission, as part of its global health mission
September 13, 2022
September 13, 2022
Phase 3 study to be initiated for second long-acting injectable antipsychotic using MedinCell’s technology
August 29, 2022
August 29, 2022
MedinCell: inclusion of first participants in new Covid-19 prophylaxis clinical trial SAIVE
March 28, 2022
March 28, 2022
MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM
September 1, 2021
September 1, 2021
MedinCell’s Long-Acting Injectable to fight Malaria ready to enter Regulatory Development
June 14, 2021
June 14, 2021
Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin
April 19, 2021
April 19, 2021
MedinCell: mdc-CWM clinical phase 3 will start in 2021
March 25, 2021
March 25, 2021
Covid-19: MedinCell publishes an extensive Ivermectin Safety Expert Analysis
